Recruiting

Testing a new combination treatment for two types of blood lymphomas

Plain-English translation of NCT06792825 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a medication called , when added to two other medications ( and ), works better for people who have just been diagnosed with follicular lymphoma or marginal zone lymphoma and have never been treated before. The study will carefully watch how well the treatment works and how safe it is for both types of lymphoma separately.

Follicular lymphoma and marginal zone lymphoma are slow-growing blood cancers, but current treatments don't work for everyone. Researchers believe that adding this medication to an existing two-drug combination might help more patients achieve remission or better control their disease.

Do you qualify?

You likely qualify if…

you have been diagnosed with either follicular lymphoma (stage 1, 2, or 3a) or marginal zone lymphoma, confirmed by a biopsy
you have never received any prior chemotherapy or systemic treatment for your lymphoma
your lymphoma needs treatment because you have bulky disease (large tumors), B symptoms like fever or night sweats, or organ involvement
you have adequate organ function (liver, kidney, heart, and lung function are healthy enough) as shown by blood tests and imaging within the last 2–4 weeks
you are willing and able to use contraception for the entire treatment period and for 12 months after, if you could have children or have a partner who could

You likely don't qualify if…

you have active hepatitis B, hepatitis C, or HIV infection
you have previously been treated with lenalidomide
you have significant nerve damage (grade 2 or higher peripheral neuropathy)
you have had another cancer in the past 5 years (other than your current lymphoma)
you have an active infection requiring antibiotics or antivirals, or received a live vaccine within 2 weeks

What participation looks like

You will receive the medication combination over 6 cycles (each cycle is about 4 weeks). In the first cycle, you'll receive intravenous infusions of and on days 1, 8, 15, and 22, plus daily oral pills. The schedule changes slightly in later cycles, with fewer infusions but continued medication. After 6 cycles, your disease will be assessed with imaging and scans, and your treatment plan will be adjusted based on how well you've responded—some patients may stop one medication while continuing others.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(1 site)

United States

Masonic Cancer Center, Minneapolis, Minnesota